Significant reduction found in risk for disease progression/death for C+R versus placebo and rituximab
Increased exposure linked to significantly increased rates of incident keratinocyte carcinoma, melanoma in adults ≥66 years
However, authors warn that stagnation and possible increase in more recent years may indicate reversal of trend
Twenty-five percent experienced CVD event during follow-up; risk up for ß-blocker use but not with calcium channel blockers, diuretics
Decrease in pulmonary vascular resistance at 24 weeks greater with sotatercept versus placebo for pulmonary arterial hypertension
